DELESTROGEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DELESTROGEN (DELESTROGEN).
Estradiol, the active component, binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and exerting estrogenic effects on the reproductive, cardiovascular, skeletal, and central nervous systems.
| Metabolism | Estradiol is metabolized primarily in the liver via phase I hydroxylation by CYP3A4 and CYP1A2, followed by conjugation (glucuronidation and sulfation) to inactive metabolites (e.g., estrone, estriol, conjugates). Enterohepatic recirculation occurs. |
| Excretion | Renal (primarily as glucuronide and sulfate conjugates, ~50-80%), fecal (~10-20%) |
| Half-life | Terminal elimination half-life: ~12-24 hours; clinical context: prolonged with hepatic impairment, steady-state achieved within ~5-7 days of daily IM dosing |
| Protein binding | ~98-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin |
| Volume of Distribution | Approximately 1-2 L/kg; indicates widespread distribution into tissues, including fat and reproductive organs |
| Bioavailability | IM (estradiol valerate): 100% (prodrug rapidly hydrolyzed to estradiol); Oral estradiol: variable ~5-10% due to first-pass metabolism |
| Onset of Action | IM injection: estradiol valerate, onset of estrogenic effects within a few hours; typical clinical response (e.g., vasomotor symptom relief) within 1-2 weeks |
| Duration of Action | IM injection: approximately 2-3 weeks for estradiol valerate; duration sufficient for once-monthly dosing in hormone therapy |
10-20 mg intramuscularly every 4 weeks for estrogen replacement therapy.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended; use with caution in severe renal impairment due to potential fluid retention. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), use lowest effective dose and monitor liver function. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Use lowest effective dose due to increased risk of thromboembolic events, cardiovascular disorders, and malignancy. Not recommended for prevention of dementia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DELESTROGEN (DELESTROGEN).
| Breastfeeding | Estrogen can decrease milk production and quality. Delestrogen is excreted in breast milk; M/P ratio is approximately 0.5-1.0. Use is contraindicated during breastfeeding due to potential adverse effects on the infant, including jaundice and transient breast enlargement. |
| Teratogenic Risk | Delestrogen (estradiol valerate) is contraindicated in pregnancy. First trimester: associated with increased risk of congenital anomalies including cardiovascular and limb defects. Second and third trimesters: risk of urogenital abnormalities in female fetuses, vaginal adenosis, and cervical dysplasia. Fetal exposure may lead to reproductive tract abnormalities and increased lifetime cancer risk. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risk of endometrial cancer, stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction. Breast cancer risk may be increased with combined estrogen-progestin therapy. Use lowest effective dose for shortest duration.
| Serious Effects |
Undiagnosed abnormal genital bleeding, known/suspected breast cancer (except for appropriately selected cases), known/suspected estrogen-dependent neoplasia, active DVT/PE or history of these conditions, active arterial thromboembolic disease (e.g., stroke, MI), known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency), known or suspected pregnancy, liver dysfunction or disease, and hypersensitivity to any component.
| Precautions | Cardiovascular disorders (stroke, DVT, PE, MI), malignancy (endometrial, breast, ovarian), dementia, gallbladder disease, hypercalcemia, visual abnormalities, fluid retention, hereditary angioedema, hypertriglyceridemia, hypothyroidism, exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas, and severe hepatic impairment. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, hepatic function, and signs of thromboembolism. Fetal monitoring includes ultrasound for growth and development if inadvertent exposure occurs. Assess for signs of androgenization in female fetuses. |
| Fertility Effects | Delestrogen suppresses gonadotropin secretion, inhibiting ovulation and spermatogenesis. Reversible effect: fertility returns upon discontinuation. Chronic use may lead to endometrial atrophy, reducing implantation potential. |